生物技术IPO市场回暖：Eikon、Agomab、SpyGlass和Veradermics引领十亿美元复苏潮流-动脉网

Biotech IPO Market Thaws: Eikon, Agomab, SpyGlass and Veradermics Lead Billion-Dollar Revival

GeneOnline 等信源发布 2026-02-09 17:41



可切换为仅中文







by Richard Chau

理查德·周

Share To

分享到

After a long winter, the IPO window reopened in early February 2026 as Eikon Therapeutics, Agomab, SpyGlass Pharma, and Veradermics raised approximately $1 billion in a single week. (Image: Canva)

经过漫长的冬季，IPO窗口于2026年2月初重新开启，Eikon Therapeutics、Agomab、SpyGlass Pharma和Veradermics在短短一周内筹集了约10亿美元。（图片来源：Canva）

he long-frozen window for biotechnology initial public offerings has been thrown wide open. In a definitive signal that risk appetite has returned to the life sciences sector, four emerging biopharma companies—Eikon Therapeutics, Agomab Therapeutics, SpyGlass Pharma, and Veradermics—successfully priced .

生物技术首次公开募股（IPO）的长久冻结窗口已被彻底打开。作为风险偏好回归生命科学领域的明确信号，四家新兴生物医药公司——Eikon Therapeutics、Agomab Therapeutics、SpyGlass Pharma和Veradermics——成功定价。

IPOs

首次公开募股

during the first week of February 2026. The flurry of listings generated nearly $1 billion in combined gross proceeds, marking the most significant week of capital formation for the industry in recent memory.

2026年2月的第一周。这一波上市热潮共筹集了近10亿美元的资金，标志着该行业近年来资本形成最为重要的一周。

This resurgence is not merely a spike in volume but a test of investor selectivity. The successful debuts of these four companies, spanning oncology, immunology, ophthalmology, and dermatology, suggest that institutional investors are once again willing to deploy capital, provided the science is robust and the commercial pathway is clear..

这种复苏不仅仅是数量上的激增，更是对投资者选择性的一次考验。这四家涵盖肿瘤学、免疫学、眼科和皮肤病学的公司成功上市，表明只要科学基础扎实且商业化路径清晰，机构投资者再次愿意投入资本。

Eikon Therapeutics Sets New High-Water Mark

Eikon Therapeutics 创下新高

The headline event of the week arrived with Eikon Therapeutics. The California-based oncology company listed on the Nasdaq with an upsized offering that

本周的头条事件来自Eikon Therapeutics。这家总部位于加利福尼亚的肿瘤学公司以超额认购的方式在纳斯达克上市，

raised $381 million

筹集了3.81亿美元

, cementing its status as the largest biotech IPO since 2024.

，巩固了其作为自2024年以来最大生物技术IPO的地位。

Eikon priced 21.2 million shares at $18 apiece, the top end of its marketed $16 to $18 range. This was a clear vote of confidence from Wall Street, as the company had initially planned to sell only 17.6 million shares. The demand allowed Eikon to secure gross proceeds significantly higher than the $273.5 million in net proceeds it had originally targeted..

Eikon以每股18美元的价格发行了2120万股，达到了其市场推广的16至18美元价格区间的上限。这是华尔街对其投出的明确信任票，因为该公司最初计划仅出售1760万股。强劲的需求使Eikon获得的总收益显著高于其最初预计的2.735亿美元净收益。

The company’s ability to command such a valuation highlights a renewed market willingness to back high-science platform plays. Eikon is capitalizing on

该公司获得如此估值的能力突显了市场重新愿意支持高科学平台型公司。Eikon 正在利用

Nobel Prize-winning

诺贝尔奖获奖的

super-resolution fluorescence microscopy to track protein dynamics in living cells, a sophisticated approach to drug discovery that has evidently resonated with public market investors.

超分辨率荧光显微镜技术追踪活细胞中的蛋白质动态，这是一种复杂的药物发现方法，显然引起了公共市场投资者的共鸣。

The financing runway provided by this IPO is substantial.

这次首次公开募股（IPO）提供的融资渠道非常可观。

According to filings

根据备案文件

, the $381 million windfall will bankroll the clinical advancement of its oncology pipeline. The total raise could climb even higher, increasing by approximately $57.2 million, if underwriters exercise their 30-day option to purchase an additional 3.2 million shares. By surpassing the $318 million raised by .

，这笔3.81亿美元的意外之财将为公司肿瘤学管线的临床进展提供资金支持。如果承销商行使30天内额外购买320万股的选择权，总募资额可能会更高，增加约5720万美元。此次募资超过了之前筹集的3.18亿美元。

Aktis Oncology

阿克蒂斯肿瘤学

in early January, Eikon has effectively reset the bar for what is possible in the 2026 market environment.

1月初，Eikon 已经有效地重新设定了2026年市场环境中可能实现的目标。

Agomab Therapeutics Brings European Innovation to NASDAQ

Agomab Therapeutics 将欧洲创新带入纳斯达克

While Eikon anchored the week with sheer size,

虽然Eikon以庞大的规模稳住了本周，

Belgian biotech Agomab Therapeutics

比利时生物技术公司Agomab Therapeutics

demonstrated that US investors remain eager for high-quality European assets. Trading under the ticker “AGMB” on the Nasdaq, Agomab priced its offering at $16 per share, squarely in the middle of its projected $15 to $17 range.

这表明美国投资者对高质量的欧洲资产仍然充满渴望。Agomab 在纳斯达克以股票代码 “AGMB” 进行交易，其发行价为每股 16 美元，正好位于其预计的 15 至 17 美元范围的中间。

The offering of 12.5 million shares generated

这次发行的1250万股产生了

$200 million in gross proceeds

2亿美元的总收益

. Agomab, which specializes in fibrosis and tissue repair, represents a strategic bet on mechanism-driven immunology. The company plans to use the capital to fund a global Phase 2b study of

Agomab公司专注于纤维化和组织修复，代表了对机制驱动免疫学的战略性押注。该公司计划利用这笔资金来资助一项全球性的2b期研究。

ontunisertib (AGMB-129)

. This oral small molecule, an ALK5 inhibitor, has previously shown promise in targeting intestinal tissue in patients with fibrostenosing Crohn’s disease.

这种口服小分子ALK5抑制剂之前已显示出在治疗纤维化克罗恩病患者的肠道组织方面具有潜力。

The funding is critical for Agomab’s strategy of positioning ontunisertib, the company’s lead candidate, as a combination therapy. The goal is to use the drug alongside existing Crohn’s treatments to halt the scarring process, a significant unmet need in the field.

这笔资金对于Agomab的战略至关重要，该战略旨在将其主要候选药物ontunisertib定位为联合疗法。目标是将该药物与现有的克罗恩病治疗方法结合使用，以阻止瘢痕形成过程，这是该领域一个重要的未满足需求。

The Agomab listing serves as a liquidity event for early backers and a validation of its M&A strategy, particularly its 2021 acquisition of Origo Biopharma, which brought ontunisertib into the pipeline. Should underwriters utilize their option to buy an additional 1.9 million shares, the company could add another $30 million to its balance sheet..

Agomab上市为早期支持者提供了流动性事件，并验证了其并购战略，尤其是2021年收购Origo Biopharma的举措，这次收购将ontunisertib引入了研发管线。如果承销商行使购买额外190万股的选择权，该公司可能会为其资产负债表再增加3000万美元。

SpyGlass Pharma Validates the MedTech-Biotech Hybrid Model

SpyGlass Pharma验证了MedTech-Biotech混合模式的有效性

Joining Agomab on the Nasdaq was

加入Nasdaq的Agomab公司

SpyGlass Pharma

间谍玻璃制药公司

, an eye-care company that bridges the gap between traditional drug development and medical devices. Trading under the ticker “SGP,” SpyGlass priced 9.4 million shares at $16 each to raise $150 million.

，这是一家填补传统药物开发和医疗器械之间空白的眼科公司。SpyGlass 以每股 16 美元的价格发行了 940 万股，筹集了 1.5 亿美元，股票代码为“SGP”。

SpyGlass offers a distinct value proposition focused on compliance and long-acting delivery. Its lead product, the Bimatoprost Drug Pad-IOL System, is an intraocular lens capable of delivering the glaucoma drug bimatoprost for multiple years. By integrating drug delivery into a device implanted during routine cataract surgery, SpyGlass aims to eliminate the daily burden of eye drops for patients..

SpyGlass 提供了一种独特价值主张，专注于合规性和长效递送。其主导产品 Bimatoprost 药物垫-IOL 系统是一种能够持续多年递送青光眼药物比马前列素的 intraocular lens（人工晶状体）。通过将药物递送整合到在常规白内障手术中植入的装置中，SpyGlass 旨在消除患者每日使用眼药水的负担。

The successful pricing of this IPO indicates strong market support for “de-risked” technologies that reformulate approved drugs into novel delivery systems. The proceeds will fund two ongoing Phase 3 clinical trials, with capital also allocated for a potential commercial launch if the data proves positive..

此次IPO的成功定价表明市场对“降低风险”技术的大力支持，这些技术将已批准的药物重新配制成新型递送系统。所得资金将用于资助两项正在进行的第三阶段临床试验，并且如果数据证明为正面，还将分配资金用于潜在的商业发布。

The SpyGlass deal also includes a standard “greenshoe” option. If underwriters purchase the additional 1.4 million shares available to them, the gross proceeds would rise by approximately $22.5 million.

SpyGlass 交易还包括一项标准的“绿鞋”期权。如果承销商购买了可供其支配的额外 140 万股，那么总收益将增加约 2,250 万美元。

Veradermics Explodes on Debut with “Oral Rogaine” Pitch

Veradermics以“口服落健”为卖点在首秀中大放异彩

If Eikon represented institutional prestige,

如果Eikon代表了机构的威望，

Veradermics

真皮层学

represented raw market enthusiasm. The Connecticut-based biotech, which is developing an oral formulation of minoxidil for hair regrowth, saw its stock price more than double on its first day of trading.

代表了市场的原始热情。这家总部位于康涅狄格州的生物技术公司正在开发一种用于毛发再生的米诺地尔口服制剂，其股票在首个交易日的价格翻了一倍多。

Listing on the New York Stock Exchange

纽约证券交易所上市

under the ticker “MANE

股票代码“MANE”

,” Veradermics priced its upsized offering at $17 per share. The company sold just over 15 million shares to raise $256.3 million. The market reaction was immediate and fierce. On Wednesday, February 4, shares soared to close at $37.75, delivering a return of over 100% to IPO investors in a single session..

Veradermics将其扩大规模的发行价定为每股17美元。该公司出售了略超过1500万股，筹集了2.563亿美元。市场反应迅速而猛烈。2月4日星期三，股价飙升至收盘价37.75美元，单日为IPO投资者带来了超过100%的回报。

Veradermics is tapping into the massive lifestyle medicine market. While oral minoxidil is used off-label, it carries cardiovascular risks. Veradermics claims its proprietary formulation mitigates these side effects while maintaining efficacy, offering a cleaner alternative to messy topical treatments.

Veradermics正在进军庞大的生活方式医学市场。虽然口服米诺地尔被非标签使用，但它有心血管风险。Veradermics声称其专有配方能减轻这些副作用，同时保持疗效，提供了一种比凌乱的外用治疗更清洁的替代方案。

The explosive trading debut suggests that generalist investors are hungry for biotech stories with easily understood commercial potential and large consumer addressable markets..

这种爆炸性的交易首秀表明，普通投资者渴望看到具有易于理解的商业潜力和庞大消费者可触达市场的生物技术故事。

A Bifurcated but Healthy Market Recovery

分叉但健康的市场复苏

The first week of February 2026 offers several key takeaways for the broader biopharma industry. First, the “mega-round” is back. Eikon’s $381 million raise proves that deep pockets are available for companies with pedigree management and differentiated platforms. The freeze that forced many companies to rely on insider extensions or reverse mergers appears to be thawing..

2026年2月的第一周为更广泛的生物制药行业提供了几个关键的要点。首先，“巨额融资”回归了。Eikon公司筹集的3.81亿美元证明，对于拥有资深管理团队和差异化平台的公司来说，资金雄厚的投资者依然存在。迫使许多公司依赖内部增资或反向并购的融资冻结似乎正在解冻。

Second, the market is discriminating but diverse. Investors are not solely focused on one therapeutic area. The week’s winners spanned cancer (Eikon), gut health (Agomab), vision (SpyGlass), and aesthetics (Veradermics). This breadth indicates a healthy ecosystem where capital is allocated based on specific clinical merit rather than sector-wide hype..

第二，市场具有辨别力但同时多样化。投资者并非只关注一个治疗领域。本周的赢家涵盖了癌症（Eikon）、肠道健康（Agomab）、视力（SpyGlass）和美学（Veradermics）。这种广度表明了一个健康的生态系统，资本是基于具体的临床价值而非整个行业的炒作来分配的。

Third, the “de-risking” premium remains real. While Eikon sold a discovery engine, SpyGlass and Veradermics sold late-stage assets based on well-understood pharmacology (bimatoprost and minoxidil). The massive pop in Veradermics stock specifically highlights a market preference for assets that are close to commercialization and carry lower biological risk..

第三，“降低风险”的溢价依然存在。虽然Eikon出售的是一个发现引擎，但SpyGlass和Veradermics出售的是基于广为人知药理学的晚期资产（比马前列素和米诺地尔）。Veradermics股票的大幅上涨特别突显了市场对接近商业化且具有较低生物学风险的资产的偏好。

As the industry moves deeper into 2026, the performance of these four classes of stock will likely serve as a barometer. If Eikon and Agomab can hold their valuations and Veradermics maintains its momentum, the backlog of private biotech companies waiting for an exit may finally begin to clear. For now, the message from Wall Street is unambiguous.

随着行业深入到2026年，这四类股票的表现可能会成为一个晴雨表。如果Eikon和Agomab能够保持其估值，而Veradermics维持其发展势头，那么等待退出的私营生物技术公司积压的情况可能最终会开始缓解。目前，华尔街传递的信息非常明确。

The window is open..

窗户是开着的。

China’s Ascentage Snatches First Biotech IPO Price of 2025, Raking in $126M

中国亚盛医药夺得2025年生物技术领域首个IPO，融资1.26亿美元

[email protected]

电子邮件地址

Author

作者

Richard Chau

理查德·周

Ranking & Reports